Trials / Recruiting
RecruitingNCT05725291
AMT-116 in Patients With Advanced Solid Tumors
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Multitude Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-116 | Administered intravenously |
Timeline
- Start date
- 2023-07-25
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2023-02-13
- Last updated
- 2025-08-17
Locations
10 sites across 3 countries: United States, American Samoa, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05725291. Inclusion in this directory is not an endorsement.